Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis

• Published in: Current pharmaceutical design Vol. 26; no. 26; p. 3171
• Main Authors: Fan, Qin, Lv, Wenhao, Xu, Yuexin, Dong, Yuan, Xiang, Zhiqiang, Wang, Junjie
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2020
• Subjects: Antibodies, Monoclonal - therapeutic use; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab - therapeutic use; Cetuximab - therapeutic use; Colorectal Neoplasms - drug therapy; Fluorouracil; Humans; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Treatment Outcome; meta-analysis; VEGFR inhibitor; randomized controlled trials; chemotherapy; Metastatic colorectal cancer; Bevacizumab

Metastatic colorectal cancer (mCRC) is one of the most common and deadly cancers worldwide. For most patients diagnosed with mCRC and managed with 5-fluorouracil (5-FU)/leucovorin plus oxaliplatin (FOLFOX), the median survival time is still less than 2 years. Small molecule selective vascular endoth...